MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ
1.135
+0.095
+9.13%
Pre Market: 1.140 +0.005 +0.44% 08:33 08/17 EDT
OPEN
1.050
PREV CLOSE
1.040
HIGH
1.195
LOW
1.040
VOLUME
718
TURNOVER
0
52 WEEK HIGH
2.530
52 WEEK LOW
0.8663
MARKET CAP
144.44M
P/E (TTM)
-7.2850
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLSA last week (0810-0814)?
Weekly Report · 13h ago
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
TipRanks · 08/10 16:30
Weekly Report: what happened at TLSA last week (0803-0807)?
Weekly Report · 08/10 09:35
Major Insider Move Signals Rising Confidence at Tiziana Life Sciences
TipRanks · 08/07 02:02
Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares
TipRanks · 08/06 13:16
Tiziana Life Sciences CEO Makes Bold Insider Move Signaling Growing Confidence
TipRanks · 08/06 02:12
Tiziana Life Sciences CEO buys 667,000 shares, boosts stake
Seeking Alpha · 08/04 12:50
Tiziana Life Sciences CEO Boosts Stake as Lead MS Therapy Progresses
TipRanks · 08/04 11:28
More
About TLSA
Tiziana Life Sciences Ltd. is a biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer’s, and Amyotrophic lateral sclerosis. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Webull offers Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ: TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.